Didanosine (ddI)

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), French National Agency for Research on AIDS and Viral Hepatitis, Institut de Recherche pour le Developpement

Conditions

AIDSHIV Infections

Phase 1

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

CompletedNCT00016718

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2001-08-31End: 2009-01-31Updated: 2021-11-05

Phase 2

Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

CompletedNCT00122538

French National Agency for Research on AIDS and Viral HepatitisAIDS, HIV Infections

Start: 2006-02-28End: 2009-05-31Updated: 2011-12-05

One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

CompletedNCT00142337

Institut de Recherche pour le DeveloppementHIV Infections

Start: 2004-12-31End: 2009-02-28Updated: 2012-01-06

Related Papers

A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.

2013-03-018 citations